CD274 and neoplasm: TCR-Ts co-expressing PD1-41BB showed more potent responses directed against PRAME-positive, PD-L1-expressing tumor cells compared to TCR-Ts lacking PD1-41BB, without altering a favorable in vitro safety profile.